当前地点：

EN

选择地点：

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

 

SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

 

The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and was commercialized in China in 2016. In 2022, SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.

 

SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program.

 

SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations.


MissionSupply vaccines to eliminate human diseases.

Our History

2022
2021
2020
2017
2016
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
1999
1996
1987
1985
1982

  • SINOVAC's Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO.


  • Poliomyelitis Vaccine (Vero Cell),Inactivated, Sabin Strains was marketed

  • COVID-19 Vaccine (Vero Cell), Inactivated—CoronaVac® was officially listed in the WHO Emergency Use Listing on June 1, 2021

  • COVID-19 Vaccine CoronaVac® has been approved for emergency use/conditional marketing in dozens of countries, including China, Chile, Turkey, Brazil, Indonesia, Etc.

  • Varicella Vaccine, Live, was marketed

  • Quadrivalent Influenza Vaccine was marketed

  • 23-valent Pneumococcal Polysaccharide Vaccine was marketed

  • Initiated the "Anti-COVID-19 Action" program to R&D Inactivated COVID-19 vaccine, CoronaVac®, which was one of the first vaccines against COVID-19 in China to be approved for emergency use

  • SINOVAC's fourth vaccine industrial base in Daxing, Beijing was put into use

  • Sinovac (Singapore) Ltd. was founded

图片关键词

  • Sinovac's Inactivated Hepatitis A vaccine, Healive®, passed and the only passed in China the prequalification assessment by WHO

图片关键词

  • The world's first class I drug for preventative biological products was marketed- Enterovirus Type 71 Inactivated Vaccine (Vero Cell),Inlive®

  • Mumps live Vaccine was marketed

图片关键词图片关键词

  • Sinovac (Dalian) Vaccine Technology Co., Ltd. was founded

  • Acquired and started to build SINOVAC's third vaccine industrial base in Changping Beijing

  • The world's first H1N1 Influenza A Inactivated Vaccine (Split Virion), Inactivated, Panfu.1®, was approved to produce for production and started massive vaccination in China


图片关键词图片关键词

  • Along of Healive® vaccine exported to Mongolia and Anflu® vaccine exported to the Philippines, SINOVAC opened the international market

  • Sinovac Life Sciences Co., Ltd. was founded

  • Sinovac Holdings was moved to the NASDAQ Global Select Market


  • China's first Pandemic Influenza Vaccine (Inactivated, Adjuvanted), PanFlu®,was approvedto be produced for government stockpiling

  • Sinovac Biotech (Hong Kong) Ltd. was founded.

  • SINOVAC was the first company to join the IFPMA in developing countries

  • Anflu®,  inactivated, Influenza Vaccine (Split Virion) was marketed

图片关键词

  • Bilive®, China's first and the world's second Hepatitis A and Hepatitis B Combined Vaccine was marketed

图片关键词图片关键词

  • The world's first SARS inactivated vaccine Phase I clinical study results was unblinded

  • Started study on pandemic influenza vaccine against human infection with highly pathogenic avian influenza (H5N1)

  • SINOVAC shares were listed on the American Stock Exchange (AMEX)

图片关键词

  • Started the development of an inactivated SARS Vaccine R&D program

  • Sinovac Holdings was listed on NASDAQ OTCBB in the United States through a reverse takeover

图片关键词图片关键词

  • China's first inactivated Hepatitis A vaccine, Healive®, was marketed

图片关键词

  • Sinovac Biotech Co., Ltd. was founded

图片关键词图片关键词

  • A "new drug certificate" was obtained for the inactivated Hepatitis A vaccine

图片关键词

  • Cooperated with the National Institute for the Control of Pharmaceutical and Biological Products to initiate the development of an inactivated Hepatitis A vaccine

图片关键词

  • Developed China's first Hepatitis A enzyme-linked diagnostic reagent

图片关键词图片关键词

  • Successfully isolated the TZ84 strain of the hepatitis A virus

Conducted an investigation into endemic areas with endemic hepatitis A

Social Responsibilities

Corporate Social Responsibility (CSR) is one of the driving forces for sustainable development of our company. We always attach great importance to social responsibility work, actively undertake corporate social responsibility, deliver healthy ideas and products to thousands of households, support the global unmet needs of disease prevention and control, promote the development of public health with practical actions, and work together with all sectors for a healthier world.

© SINOVAC All rights reserved